Stock Markets April 28, 2026 06:39 AM

Kimberly-Clark Holds 2026 Guidance After Q1 Sales Top Estimates as Volumes Offset Price Cuts

Lower Kleenex prices and new, value-focused product introductions supported volume gains even as margins tightened

By Jordan Park KMB
Kimberly-Clark Holds 2026 Guidance After Q1 Sales Top Estimates as Volumes Offset Price Cuts
KMB

Kimberly-Clark maintained its full-year outlook for fiscal 2026 and reported first-quarter sales that exceeded analyst expectations, driven by volume growth from new product launches and expanded affordable offerings. Price declines and strategic investments compressed margins, but the company reaffirmed a double-digit adjusted EPS growth target on a constant-currency basis and reiterated its expected closing of the $40 billion Kenvue acquisition in the second half of 2026.

Key Points

  • Q1 sales of $4.16 billion topped the $4.09 billion analyst consensus.
  • Organic sales rose 2.5% driven by a 2.6% increase in volumes despite a 0.5% decline in prices.
  • Company reaffirmed fiscal 2026 guidance and expects to close the $40 billion Kenvue acquisition in H2 2026.

Kimberly-Clark kept its annual guidance intact while posting first-quarter results that beat sales estimates, a performance the company attributed to resilient consumer demand for personal care and hygiene products despite broader macroeconomic and geopolitical uncertainty.

For the quarter ended March 31, the company said prices were down 0.5% while organic sales rose 2.5%. That organic growth reflected a 2.6% increase in total volumes, supported by momentum from recent product launches and an expanded suite of lower-priced options designed to appeal to budget-conscious shoppers. The company noted that these shifts helped offset a pullback in pricing and heightened competition across its categories.

Kimberly-Clark reported first-quarter net sales of $4.16 billion, topping the LSEG-compiled analyst consensus of $4.09 billion. Management reiterated its expectation to complete the roughly $40 billion acquisition of Kenvue, the maker of Tylenol, in the second half of 2026.

The Dallas-based maker of Huggies diapers said it expects fiscal 2026 organic sales growth to be in line with or ahead of the weighted average growth rate of the categories and markets in which it operates - a reference point that has expanded by about 2.5% over the latest 12 months. The company continues to forecast adjusted earnings per share growth in the double digits on a constant-currency basis.

Despite top-line strength, margins were squeezed. The company cited a sequential decline in selling prices along with higher spending on product innovation and supply-chain initiatives. Those factors eroded the gains from earlier cost actions, which included workforce reductions and divestiture of lower-margin operations such as private-label diapers and personal protective equipment businesses.

On a quarterly basis, adjusted gross margin contracted by 60 basis points to 37.9%.


Key takeaways

  • Sales beat expectations: Q1 revenue of $4.16 billion exceeded the $4.09 billion consensus.
  • Volume-driven growth: Organic sales climbed 2.5% on a 2.6% rise in volumes despite a 0.5% price decline.
  • Guidance and acquisition timeline affirmed: Company keeps 2026 outlook and expects to close the $40 billion Kenvue deal in H2 2026.

Risks and uncertainties

  • Margin pressure - Pricing declines and elevated investments in innovation and supply chain have compressed gross margins, which could continue to weigh on profitability.
  • Competitive environment - Intense competition and demand softness in certain channels may challenge future pricing power and volume performance.
  • Integration and timing risk - The planned Kenvue acquisition closing in the second half of 2026 carries customary execution and timing uncertainties.

Overall, Kimberly-Clark's report painted a picture of a consumer goods company navigating a trade-off between protecting volume through lower prices and investing in growth initiatives, while holding firm to its near-term financial objectives.

Risks

  • Margin compression due to sequential price declines and higher investments in product innovation and supply chain - impacts profitability and could affect financial performance in consumer goods and retail sectors.
  • Intense competition and demand slowdowns may limit pricing power and volume growth - affecting consumer staples and retail markets.
  • Execution and timing uncertainty around the planned Kenvue acquisition - could affect corporate integration and capital allocation in the healthcare/consumer health sector.

More from Stock Markets

Bertelsmann to Merge BMG with Concord, Forming World’s Fourth‑Largest Music Group Apr 28, 2026 Bernstein Identifies Snam, Italgas and Metlen as Primary Winners from Greece's Energy Transition Apr 28, 2026 S&P Global Posts Higher Q1 Profit as Demand for Analytics Strengthens Apr 28, 2026 Oracle and CoreWeave Stocks Slide After Report Raises Questions About OpenAI Growth Apr 28, 2026 Chip Stocks Slide After Report Says OpenAI Missed Key User and Revenue Targets Apr 28, 2026